Glucocorticoid-induced osteoporosis prevention in polymyalgia rheumatica patients
Loading...
Date
2020
Authors
Swami, Tara
Molloy, C.
Journal Title
Journal ISSN
Volume Title
Publisher
Irish Medical Organisation
Published Version
Abstract
Aim: Studies indicate that <50% of polymyalgia rheumatica (PMR) patients receive bone protective therapy (BPT) for glucocorticoid-induced osteoporosis (GIOP) prevention. We sought to determine if PMR patients are protected from GIOP by examining bone densitometry (DXA) scan results, BPT use, and adherence to guidelines. Methods: PMR patients treated with glucocorticoids who underwent a DXA scan at Cork University Hospital from 01/01/2016 to 27/10/2017 were included. Patient data were obtained from chart review. Results: Out of 153 patients, 73 (47.7%) were taking BPT and 42 (27.5%) were not. At the most recent DXA scan, 42 (27.5%) had normal BMD, 84 (54.9%) were osteopaenic, and 27 (17.6%) were osteoporotic. In 91 individuals who underwent≥2 DXA scans, patients not receiving bisphosphonates were more likely to have BMD loss over time (p=0.022). Discussion: Despite recommendations, many patients are not prescribed BPT. The results suggest that PMR patients in Cork are not optimally protected from GIOP.
Description
Keywords
Polymyalgia rheumatica , PMR , Bone protective therapy , BPT , Glucocorticoid-induced osteoporosis , GIOP
Citation
Swami, T. and Molloy, C. (2020) 'Glucocorticoid-induced osteoporosis prevention in polymyalgia rheumatica patients' Irish Medical Journal, 113(3), P36 (7pp). Available at: http://www.imj.ie/wp-content/uploads/2020/03/Glucocorticoid-Induced-Osteoporosis-Prevention-in-Polymyalgia-Rheumatica-Patients.pdf (Accessed: 21 September 2021)
Link to publisher’s version
Collections
Copyright
© 2020, Irish Medical Journal. All rights reserved.